ArticleJournal of health, population, and nutrition2025
Initial different human papillomavirus infection statuses and subsequent infection risk: a decade-long longitudinal study.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Role of Enterococcus faecium in the Synergistic Clearance of High-Risk HPV: A Clinical Study on Cervicovaginal Microbiota Regulation.Cancer medicine · 2026Article
- Article
- Development and internal validation of a vaginal microecology-based multivariable prediction model for persistent high-risk human papillomavirus infection: a retrospective study.Frontiers in medicine · 2026Article
- Risk-stratified surveillance after LEEP: a nomogram integrating HPV persistence, margin status, and clinical factors to predict CIN2+ recurrence.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHPV infection is a major risk factor for cervical cancer. HPV vaccine coverage remains low. Early identification of high-risk individuals with some characteristics is crucial for those with limited vaccination access.
objectiveTo estimate the impact of different HPV infection statuses on subsequent infection, infection type, and coinfection. Influencing factors of long-term HPV infection status and clearance were also explored.
methodsData from Wuxi's cervical cancer screening (2013-2022) was used. Multivariate and multinomial logistic regression models were used to evaluate the relationship between different HPV infection statuses in the first four rounds and subsequent (the fifth round) infection, infection type, and coinfection, and the influencing factors on different HPV infection statuses during the five rounds, respectively. Survival analysis was applied to explore the HPV clearance.
resultsA total of 20,817 females were included. Those experienced two or more HPV infections had the highest likelihood of being subsequent infection (Two or more vs. One: OR = 2.11, 95%CI: 1.61 ~ 2.76, P < 0.001). The risk of subsequent infection increases progressively (versus sustained infection-free) in one classification of HPV infection: a single transient infection (OR = 5.72, 95%CI: 4.66 ~ 7.01, P < 0.001), persistent infection (positivity in ≥ 2 consecutive rounds; OR = 10.78, 95%CI: 8.04 ~ 14.44, P < 0.001), reinfection (reversion to positivity after prior clearance; OR = 18.51, 95%CI: 11.58 ~ 29.57, P < 0.001), and lowest among those who cleared infection with no recurrence (OR = 2.99, 95%CI: 2.32 ~ 3.84, P < 0.001), highest among those with unsolved infection (OR = 23.21, 95%CI: 18.29 ~ 29.45, P < 0.001) or reinfection (OR = 18.79, 95%CI: 11.51 ~ 30.04, P < 0.001) in another classification. HPV infection status seemed not to associate with subsequent infection types and coinfection. Baseline age, at least one coinfections and HPV 16/18 infection may influence long-term HPV infection status. The median duration for HPV clearance is 1.98 years (95%CI:1.96 ~ 2.00), which significantly affected by baseline age (HR = 0.99, 95%CI: 0.98 ~ 0.99, P < 0.001) and history of coinfection (HR = 0.50, 95%CI: 0.80 ~ 1.02, P < 0.001).
conclusionsWhen HPV vaccination coverage remains suboptimal, early identification of high-risk cervical cancer populations should prioritize characteristics including multiple/persistent/recurrence infection, coinfection, high-risk types infection, advanced age, and prolonged viral clearance time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.